Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 8Fluorouracil 5Cisplatin 5Leucovorin 4Oxaliplatin 3becatecarin 2Capecitabine 2seribantumab 1sargramostim 1pembrolizumab 1pazopanib 1motexafin lutetium 1ixabepilone 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1durvalumab 1devimistat 1cediranib 1Trastuzumab 1Sorafenib 1Radiosurgery 1Psychiatric Rehabilitation 1Palonosetron 1Observation 1Liver Transplantation 1Folfox protocol 1Escitalopram 1Erlotinib Hydrochloride 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gallbladder Neoplasms × devimistat × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡